Maxim Group Reiterates $7.00 Price Target for BioNano Genomics (NASDAQ:BNGO)

Maxim Group set a $7.00 target price on BioNano Genomics (NASDAQ:BNGO) in a research report report published on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the stock.

Several other analysts also recently commented on the stock. ValuEngine upgraded shares of BioNano Genomics from a hold rating to a buy rating in a report on Thursday. Zacks Investment Research downgraded shares of BioNano Genomics from a hold rating to a sell rating in a report on Monday, July 8th.

Shares of BNGO stock opened at $2.33 on Wednesday. The company has a quick ratio of 5.64, a current ratio of 5.94 and a debt-to-equity ratio of 3.13. The firm has a market cap of $28.31 million and a P/E ratio of -0.89. The business’s 50 day moving average is $2.61. BioNano Genomics has a 52 week low of $2.01 and a 52 week high of $10.00.

BioNano Genomics (NASDAQ:BNGO) last announced its earnings results on Thursday, May 9th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.12). The business had revenue of $1.85 million for the quarter, compared to analysts’ expectations of $1.76 million. On average, sell-side analysts forecast that BioNano Genomics will post -2.25 earnings per share for the current year.

An institutional investor recently bought a new position in BioNano Genomics stock. Millennium Management LLC acquired a new stake in BioNano Genomics Inc (NASDAQ:BNGO) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 48,399 shares of the company’s stock, valued at approximately $254,000. Millennium Management LLC owned about 0.48% of BioNano Genomics as of its most recent SEC filing. Institutional investors and hedge funds own 9.81% of the company’s stock.

BioNano Genomics Company Profile

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Further Reading: Trading based on a resistance level

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with's FREE daily email newsletter.